AREVA: Bpifrance to Support AREVA Med and Its Partners in Developing New Lead-212 Treatments for Cancer

Regulatory News:

Areva Med, the medical subsidiary of AREVA (Paris:AREVA), and its partners will benefit from the support of Bpifrance in their CARAT Project (Consortium for alpha radiotherapy applications). With a total budget of 19.7 million euros, this project will receive 9.6 million euros in financing under the French future investment program managed by the Commissariat Général à l’Investissement (CGI - French General Investment Commission).

Classified as a decisive research and development project for competitiveness (PSPC), CARAT aims to develop a French sector for the production of lead-212 and for treatments which use this rare metal to treat cancers that currently have limited therapeutic options.

Coordinated by AREVA Med, CARAT unites the companies EVEON and Triskem International, the Limoges university hospital, the CRIBL* laboratory at Limoges university and Subatech.

Patrick Bourdet, president and CEO of AREVA Med, said: "This demonstrates the confidence of the French Government along with that of our partners, with whom we share great ambitions for the development of powerful, targeted radiopharmaceuticals to combat certain particularly aggressive forms of cancer.”

The CARAT Project has also been recognized by the Lyonbiopôle and Atlanpole Biothérapies competitiveness clusters.

*Control of the B Cell Immune Response and Lymphoproliferations

About AREVA Med
AREVA Med is an AREVA subsidiary formed in 2009 to develop new therapies to fight cancer. AREVA Med has developed a unique process to extract lead-212 (²¹²Pb), a rare metal used in targeted alpha therapy (TAT), a novel approach which targets and destroys cancer cells, while limiting the impact on nearby healthy cells. AREVA Med collaborates with world-renowned scientific partners, and formed a strategic global alliance with Roche in 2012, to create a new advanced alpha radioimmunotherapy platform. For more information: www.arevamed.com. Follow @AREVAmed on Twitter.

MORE ABOUT AREVA
AREVA supplies high added-value products and services to support the operation of the global nuclear fleet.
The company is present throughout the entire nuclear cycle, from uranium mining to used fuel recycling, including nuclear reactor design and operating services.
AREVA is recognized by utilities around the world for its expertise, its skills in cutting-edge technologies and its dedication to the highest level of safety.
Through partnerships, the company is active in the renewable energy sector.
AREVA’s 44,000 employees are helping build tomorrow’s energy model: supplying ever safer, cleaner and more economical energy to the greatest number of people.

Tour AREVA – 1 Place Jean Millier – 92400 COURBEVOIE – France – Tel : +33 (0)1 34 96 00 00 – Fax : +33 (0)1 34 96 00 01

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701006266/en/